Literature DB >> 31492822

Variant type is associated with disease characteristics in SDHB, SDHC and SDHD-linked phaeochromocytoma-paraganglioma.

Jean Pierre Bayley1, Birke Bausch2, Johannes Adriaan Rijken3, Leonie Theresia van Hulsteijn4, Jeroen C Jansen5, David Ascher6, Douglas Eduardo Valente Pires7, Frederik J Hes8, Erik F Hensen5, Eleonora P M Corssmit4, Peter Devilee9, Hartmut P H Neumann10.   

Abstract

BACKGROUND: Pathogenic germline variants in subunits of succinate dehydrogenase (SDHB, SDHC and SDHD) are broadly associated with disease subtypes of phaeochromocytoma-paraganglioma (PPGL) syndrome. Our objective was to investigate the role of variant type (ie, missense vs truncating) in determining tumour phenotype.
METHODS: Three independent datasets comprising 950 PPGL and head and neck paraganglioma (HNPGL) patients were analysed for associations of variant type with tumour type and age-related tumour risk. All patients were carriers of pathogenic germline variants in the SDHB, SDHC or SDHD genes.
RESULTS: Truncating SDH variants were significantly over-represented in clinical cases compared with missense variants, and carriers of SDHD truncating variants had a significantly higher risk for PPGL (p<0.001), an earlier age of diagnosis (p<0.0001) and a greater risk for PPGL/HNPGL comorbidity compared with carriers of missense variants. Carriers of SDHB truncating variants displayed a trend towards increased risk of PPGL, and all three SDH genes showed a trend towards over-representation of missense variants in HNPGL cases. Overall, variant types conferred PPGL risk in the (highest-to-lowest) sequence SDHB truncating, SDHB missense, SDHD truncating and SDHD missense, with the opposite pattern apparent for HNPGL (p<0.001).
CONCLUSIONS: SDHD truncating variants represent a distinct group, with a clinical phenotype reminiscent of but not identical to SDHB. We propose that surveillance and counselling of carriers of SDHD should be tailored by variant type. The clinical impact of truncating SDHx variants is distinct from missense variants and suggests that residual SDH protein subunit function determines risk and site of disease. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  zzm321990SDHBzzm321990; zzm321990SDHCzzm321990; zzm321990SDHDzzm321990; Succinate dehydrogenase; genotype-phenotype; paraganglioma; pheochromocytoma

Year:  2019        PMID: 31492822     DOI: 10.1136/jmedgenet-2019-106214

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  8 in total

1.  A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy.

Authors:  Karel Pacak; Mark Kidd; Leah Meuter; Irvin M Modlin
Journal:  Endocr Relat Cancer       Date:  2021-10-13       Impact factor: 5.900

2.  A need to tailor surveillance based on family history: describing a highly penetrant familial paraganglioma kindred with an SDHD pathogenic variant.

Authors:  Madeline Foley; Anu Sharma; Kinley Garfield; Luke Maese; Luke Buchmann; Julie Boyle; Wendy Kohlmann; Joanne Jeter; Samantha Greenberg
Journal:  Fam Cancer       Date:  2022-10-12       Impact factor: 2.446

Review 3.  Hypothesis: Why Different Types of SDH Gene Variants Cause Divergent Tumor Phenotypes.

Authors:  Jean-Pierre Bayley; Peter Devilee
Journal:  Genes (Basel)       Date:  2022-06-07       Impact factor: 4.141

4.  Pheochromocytoma due to a novel SDHD variant presenting as unilateral visual loss.

Authors:  Clare Miller; Agnieszka Pazderska; John Reynolds; Patricia Gou; Barbara Dunne; Kealan McElhinney; Lisa Owens
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2021-12-01

Review 5.  Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches.

Authors:  Mickey J M Kuo; Matthew A Nazari; Abhishek Jha; Karel Pacak
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-12       Impact factor: 6.055

6.  mCSM-membrane: predicting the effects of mutations on transmembrane proteins.

Authors:  Douglas E V Pires; Carlos H M Rodrigues; David B Ascher
Journal:  Nucleic Acids Res       Date:  2020-07-02       Impact factor: 16.971

7.  Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity.

Authors:  Leonille Schweizer; Felix Thierfelder; Christian Thomas; Patrick Soschinski; Abigail Suwala; Damian Stichel; Annika K Wefers; Lars Wessels; Martin Misch; Hee-Yeong Kim; Ruben Jödicke; Daniel Teichmann; David Kaul; Johannes Kahn; Michael Bockmayr; Martin Hasselblatt; Alexander Younsi; Andreas Unterberg; Bettina Knie; Jan Walter; Diaa Al Safatli; Sven-Axel May; Andreas Jödicke; Georgios Ntoulias; Dag Moskopp; Peter Vajkoczy; Frank L Heppner; David Capper; Wolfgang Hartmann; Christian Hartmann; Andreas von Deimling; David E Reuss; Anne Schöler; Arend Koch
Journal:  Acta Neuropathol       Date:  2020-09-14       Impact factor: 17.088

8.  Distinguishing between PTEN clinical phenotypes through mutation analysis.

Authors:  Stephanie Portelli; Lucy Barr; Alex G C de Sá; Douglas E V Pires; David B Ascher
Journal:  Comput Struct Biotechnol J       Date:  2021-05-21       Impact factor: 7.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.